Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö > ºÐÀÚÇ¥ÀûÄ¡·á(MTT) > ¼¼°èÀÇ Å°³ª¾ÆÁ¦ ÀúÇØÁ¦ ½ÃÀå
Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (1590)
°Ô³ð â¾à (202)
¸ÂÃãÇüÀÇ·á (51)
¹ÙÀÌ¿À¸¶Ä¿ (154)
¹ÙÀÌ¿À¸ÅÆ®¸®¾ó (54)
¹ÙÀÌ¿ÀÀåºñ (357)
ºÐÀÚÇ¥ÀûÄ¡·á(MTT) (131)
À¯ÀüÀÚ Ä¡·á/RNAi (101)
Àç»ýÀÇÇÐ (124)
Ç×ü/¸é¿ª (191)
½ÃÀ庸°í¼­

¼¼°èÀÇ Å°³ª¾ÆÁ¦ ÀúÇØÁ¦ ½ÃÀå

Kinase Inhibitors: Global Markets

¸®¼­Ä¡»ç BCC Research
¹ßÇàÀÏ 2009³â 11¿ù »óǰÄÚµå 104223
ÆäÀÌÁö Á¤º¸ 184 pages
°¡°Ý
US $ 4,850 £Ü 5,778,700 PDF by E-mail (Single User License)
US $ 5,950 £Ü 7,089,400 PDF by E-mail (Business Unit License)
US $ 8,500 £Ü 10,127,700 PDF by E-mail (Enterprise License)


BCC Research ¿¡¼­ 2009³â 11¿ù ¿¡ ¹ßÇàÇÑ ¡¸¼¼°èÀÇ Å°³ª¾ÆÁ¦ ÀúÇØÁ¦ ½ÃÀ塹 º¸°í¼­´Â 184 pages·Î ±¸¼ºµÇ¾î, US $4,850 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Ű³ª¾ÆÁ¦ ÀúÇØÁ¦ ½ÃÀåÀÇ ÇöȲ°ú Àü¸Á¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, Á¦Ç° À¯Çü¡¤Àû¿ë Áúº´ ±¸ºÐº° ½ÃÀå ±Ô¸ð ½ÇÀû¡¤¿¹Ãø(¡­2014³â), ½ÃÆÇ Á¦Ç°°ú °³¹ßÁßÀÎ Á¦Ç°ÀÇ °³¿ä, ÁÖ¿ä ±â¾÷°ú ½ÃÀå Á¡À¯À², ±¹Á¦Àû Àü¸Á, ÇâÈÄÀÇ ¹æÇ⼺ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

    Á¦1Àå ¼­·Ð
    Á¦2Àå ¿ä¾à
    Á¦3Àå °³¿ä
    Á¦4Àå ±â¼ú °³¿ä
    • °³¹ß ÇÁ·Î¼¼½º
    • ¼ÒºÐÀÚ Å°³ª¾ÆÁ¦ ÀúÇØÁ¦
    • ATP °æÀï ÀúÇØÁ¦
    • ºñ ATP °æÀï ÀúÇØÁ¦
    • ¸ð³ëÅ©·Î³Î Ç×ü
    • ƯÀ̼ºÀÇ °úÁ¦
    • ´Ü¹éÁúÀÇ ±¸Á¶¿Í ¸ðµ¨¸µ
    • ÇÕ¸®Àû ¼³°è
    Á¦5Àå Æ¯Ç㠺м®
    Á¦6Àå ¼ö¿ëüÇü Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦ ½ÃÀå
    • Àüü ½ÃÀå ±Ô¸ð
    • ¼ö¿ëüÇü Ƽ·Î½Å Ű³ª¾ÆÁ¦ÀÇ ¹ÙÀ̿÷¯Áö(EGFR¡¤HER2¡¤HER3¡¤HER4)
    • °³¿ä : EGFR/HER ÆÐ¹Ð¸®ÀÇ ´Ü¹éÁúŰ³ª¾ÆÁ¦
    • ÀÌ¿ëÁßÀÎ EGFR ÀúÇØÁ¦
    • ¹Ì±¹ FDAÀÇ ½ÂÀÎ
    • ÀϺ»ÀÇ ¿ì¼± ½É»ç
    • IRESSAÀÇ ½ÃÆÇ ÈÄ Á¶»ç
    • ¼¼°èÀÇ EGFR ÀúÇØÁ¦ ½ÃÀå
    • ÀÓ»ó°³¹ßÁßÀÎ EGFR ÀúÇØÁ¦
    • ÀÌ¿ëÁßÀÎ HER2 ÀúÇØÁ¦
    • ÀÓ»ó°³¹ßÁßÀÎ HER2 ÀúÇØÁ¦
    • ¼¼°èÀÇ HER2 ÀúÇØÁ¦ ½ÃÀå
    • VEGF ¼ö¿ëü ÆÐ¹Ð¸® ÀúÇØÁ¦
    • ÀÌ¿ëÁßÀÎ VEGF ¼ö¿ëü ÀúÇØÁ¦
    • ÀÓ»ó°³¹ßÁßÀÎ VEGFR ÀúÇØÁ¦
    • ¼¼°èÀÇ VEGFR ÀúÇØÁ¦ ½ÃÀå
    • PDGF ¼ö¿ëü ÆÐ¹Ð¸® ÀúÇØÁ¦
    • ÀÓ»ó°³¹ßÁßÀÎ PDGFR ÆÐ¹Ð¸® ÀúÇØÁ¦
    • INS ¼ö¿ëü ÆÐ¹Ð¸® ÀúÇØÁ¦
    • ÀÓ»ó°³¹ßÁßÀÎ INS ¼ö¿ëü ÆÐ¹Ð¸® ÀúÇØÁ¦
    Á¦7Àå ºñ¼ö¿ëüÇü Ƽ·Î½Å Ű³ª¾ÆÁ¦ ¾ïÁ¦Á¦ ½ÃÀå
    • Àüü ½ÃÀå ±Ô¸ð¡¤¹è°æ
    • ABL Ű³ª¾ÆÁ¦
    • °³¿ä
    • ÀÌ¿ëÁßÀÎ ABL ÀúÇØÁ¦
    • °³¹ßÁßÀÎ ABL ÀúÇØÁ¦
    • ¼¼°èÀÇ ABL ÀúÇØÁ¦ ½ÃÀå
    • SRC Ű³ª¾ÆÁ¦
    • ÀÌ¿ëÁßÀÎ SRC Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
    • ÀÓ»ó°³¹ßÁßÀÎ SRC Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
    • JAK Ű³ª¾ÆÁ¦
    • ÀÓ»ó°³¹ßÁßÀÎ JAK ÀúÇØÁ¦
    • FAKS
    • ÀÓ»ó°³¹ßÁßÀÎ FAK ÀúÇØÁ¦
    Á¦8Àå ¼¼¸°/Æ®·¹¿À´Ñ Ű³ª¾ÆÁ¦ ÀúÇØÁ¦ ½ÃÀå
    • Àüü ½ÃÀå ±Ô¸ð
    • MTOR Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
    • RHO ÆÐ¹Ð¸® Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
    • CDK ÀúÇØÁ¦
    • ´Ü¹éÁúŰ³ª¾ÆÁ¦ C ÀúÇØÁ¦
    • PI3 Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
    • ¿À·Î¶ó Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
    • MAP/MEK Ű³ª¾ÆÁ¦ ÀúÇØÁ¦
    • JNK ÀúÇØÁ¦
    Á¦9Àå Ű³ª¾ÆÁ¦ ÀúÇØÁ¦ ½ÃÀå : Áúº´ ±¸ºÐº°
    • Àüü ½ÃÀå ±Ô¸ð
    • ¾Ï
    • ¸é¿ª¡¤¿°Áõ¼º Áúȯ
    • ½ÉÇ÷°ü°è Áúȯ
    • »õ·Î¿î ¾ÖÇø®ÄÉÀ̼Ç
    • ´ç´¢º´
    • Ȳ¹Ýº¯¼º
    • ½Å°æ°è Áúȯ
    Á¦10Àå ÁÖ¿ä ±â¾÷¡¤½ÃÀå Á¡À¯À²
    Á¦11Àå ±¹Á¦Àû Àü¸Á¡¤±ÔÁ¦»ó °úÁ¦
    Á¦12Àå ÇâÈÄÀÇ ¹æÇ⼺
LSH
Back to Top